Among the many charts and secrets contained in Snap's IPO filing is one interesting graph that shows what happens when a paid feature becomes free. Snap's lesson: People use it more.

(function () { var attempt = 0, init = function(){ if (window.pym) { var pymParent = new pym.Parent("g-2017-02-02-lens-box", "https://graphics.axios.com/2017-02-02-lens/2017-02-02-lens.html", {}); } else if (attempt++ < 40) { setTimeout(init, 50); } }; init(); })();

Reproduced from Snapchat's IPO filing

Context: Snapchat introduced "lenses," animated overlays for decorating selfies, in September 2015 and a couple of months later, opened up a "store" where users could purchase additional ones. But by January 2016, the company dropped the store idea and all lenses became free.

As the graph above, reproduced for the company's IPO filing, shows, people used the lenses less when a fee was added, and significantly more when they all became free again. As Snap puts it:

"We also learned something exciting about building new products: if we built more Creative Tools and made them available to everyone for free, our users would create more Snaps and spend more time on Snapchat.

Go deeper

FBI director says China aims to become "world's only superpower"

FBI Director Christopher Wray speaks to the media during a news conference at FBI Headquarters on June 14, 2018 in Washington, DC. Photo: Mark Wilson/Getty Images

FBI Director Christopher Wray gave a speech today at the Hudson Institute in Washington, D.C. in which he laid out "more detail on the Chinese threat than the FBI has ever presented in an open forum."

Why it matters: China's increasingly aggressive behavior under General Secretary Xi Jinping is ringing alarm bells in the U.S.

28 mins ago - Health

Trump administration invests $2 billion in coronavirus drugs

A Novavax researcher prepares to test the vaccine. Photo: Andrew Caballero-Reynolds/AFP via Getty Images

The Department of Health and Human Services and Department of Defense have awarded $1.6 billion to Novavax and $450 million to Regeneron Pharmaceuticals as part of the federal government's efforts to speed up the development of coronavirus treatments.

The bottom line: Federal scientists are holding out hope that these companies' treatments, along with other vaccines in development, will snuff out the spread of the coronavirus.

Breaking down the PPP disclosure debacle

Illustration: Eniola Odetunde/Axios

The U.S. Treasury Department Monday morning released the names over 660,000 small businesses that received Paycheck Protection Program loans of at least $150,000, per its recent compromise with Congress. Well, at least that's what we thought Treasury did.

What happened: Within hours, several well-known companies and investment firms on the list denied that they had ever applied for PPP loans, let alone received them.